High Tide’s decision to acquire 51% of Remexian Pharma for a preliminary €27.2 million isn’t just another headline; it’s a calculated entry into Europe’s largest medical cannabis market with a player that already moves real volume and runs a fully certified EU-GDP warehouse. The agreement includes an option to buy the remaining stake and is subject to regulatory approvals (including the TSX Venture Exchange). hightideinc.com + PR Newswire
Why this deal matters now
Remexian isn’t a paper asset. On High Tide’s numbers, the distributor generated annualized revenue of €70 million and adjusted EBITDA of €15 million for the six months ended March 2025. In Q2 2025, Remexian sold ~7 tonnes of flower in Germany—roughly 16% of the quarter’s import volume—underscoring that this is a scale operator, not an aspirational plan. hightideinc.com
Read more
High Tide x Remexian: A Clear Signal—and a Stress Test—for Germany’s Medical Cannabis Market
